1. Hypophosphatasia: Canadian update on diagnosis and management

   • A.A. Khan
   • R. Josse
   • C.R. Greenberg

   Consensus Statement 26 March 2019 Pages: 1713 - 1722

   

2. Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials

   • W.-C. Chen
   • E.-Y. Lin
   • Y.-N. Kang

   Review 01 May 2019 Pages: 1723 - 1732

   

3. Fracture risk following intermission of osteoporosis therapy

   • E.M. Dennison
   • C. Cooper
   • On behalf of the IOF Epidemiology/Quality of Life Working Group

   Original Article 07 June 2019 Pages: 1733 - 1743

   

4. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom

   • A. Svedbom
   • P. Hadji
   • B. Stollenwerk

   Original Article 03 July 2019 Pages: 1745 - 1754

   

5. Biochemical markers of bone turnover and risk of incident hip fracture in older women: the Cardiovascular Health Study

   • D. Massera
   • S. Xu
   • J. R. Kizer

   Original Article 21 June 2019 Pages: 1755 - 1765

   

6. History of cardiovascular disease and cardiovascular biomarkers are associated with 30-day mortality in patients with hip fracture

   • D. Norring-Agerskov
   • C. M. Madsen
   • H. L. Jørgensen

   Original Article 04 July 2019 Pages: 1767 - 1778

   

7. Secondary prevention of osteoporotic fractures: evaluation of the Lille University Hospital’s Fracture Liaison Service between January 2016 and January 2018

   • A. Pflimlin
   • A. Gournay
   • J. Paccou

   Original Article 05 June 2019 Pages: 1779 - 1788

   

8. The association between prevalent vertebral fractures and bone quality of the distal radius and distal tibia as measured with HR-pQCT in postmenopausal women with a recent non-vertebral fracture at the Fracture Liaison Service

   • L. Vranken
   • C. E. Wyers
   • J. P. W. van den Bergh

   Original Article Open access 17 July 2019 Pages: 1789 - 1797

   

9. Bone mineral density in diabetes and impaired fasting glucose

   • K. L. Holloway-Kew
   • N. Marijanovic
   • M. A. Kotowicz

   Original Article 31 July 2019 Pages: 1799 - 1806

10. Bone mass density and bone metabolism marker are associated with progression of carotid and cardiac calcified plaque in Chinese elderly population

    • D. Liu
    • L. Chen
    • R. Zhou

    Original Article 10 June 2019 Pages: 1807 - 1815

    

11. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?

    • P. K. Kristensen
    • V. Ehrenstein
    • A. B. Pedersen

    Original Article 29 June 2019 Pages: 1817 - 1825

    

12. The combined effect of Parathyroid hormone (1–34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial

    • D. B. Jepsen
    • J. Ryg
    • T. Masud

    Original Article Open access 15 July 2019 Pages: 1827 - 1836

    

13. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program

    • M.A. van Maren
    • C.E. Wyers
    • J.P.W. van den Bergh

    Original Article Open access 18 July 2019 Pages: 1837 - 1844

    

14. Saving bones without risking brain—bisphosphonates and risk of stroke: matched case-control study

    • Z. B. Asghar
    • A. Godoy Caballero
    • A. Niroshan Siriwardena

    Original Article 17 June 2019 Pages: 1845 - 1854

    

15. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

    • J.P. Bilezikian
    • C.J.F. Lin
    • A. Chines

    Original Article Open access 14 June 2019 Pages: 1855 - 1864

    

16. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap

    • J.K. Ban
    • B.B. Hao
    • S.M. Cadarette

    Original Article 17 July 2019 Pages: 1865 - 1872

    

17. WNT3A accelerates delayed alveolar bone repair in ovariectomized mice

    • Y. Liu
    • Z. Li
    • J.A. Helms

    Original Article 23 July 2019 Pages: 1873 - 1885

    

18. Nutritional hypophosphatemic rickets secondary to Neocate® use

    • S. Akhtar Ali
    • A. Mathalikunnel
    • P. Pitukcheewanont

    Case Report 29 May 2019 Pages: 1887 - 1891

    

19. Diffuse, fracturing systemic skeletal histiocytosis of unknown type: a novel metabolic bone disease

    • R. Saini
    • L. M. DiFrancesco
    • G. A. Kline

    Case Report 30 May 2019 Pages: 1893 - 1896

    

20. Correction to: The factor-of-risk biomechanical approach predicts hip fracture in men and women: the Framingham Study

    • A.B. Dufour
    • B. Roberts
    • M.T. Hannan

    Correction 01 July 2019 Pages: 1897 - 1897

21. Correction to: Secondary prevention of osteoporotic fractures: evaluation of the Lille University Hospital’s Fracture Liaison Service between January 2016 and January 2018

    • A. Pflimlin
    • A. Gournay
    • J. Paccou

    Correction 08 July 2019 Pages: 1899 - 1899

22. Correction to: Prevalent vertebral fractures and minor vertebral deformities analyzed by vertebral fracture assessment (VFA) increases the risk of incident fractures in postmenopausal women: the FRODOS study

    • E. Kanterewicz
    • E. Puigoriol
    • P. Peris

    Correction 17 July 2019 Pages: 1901 - 1902